Join today and have your say! It’s FREE!

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Please Try Again
{{ error }}
By providing my email, I consent to receiving investment related electronic messages from Stockhouse.

or

Sign In

Please Try Again
{{ error }}
Password Hint : {{passwordHint}}
Forgot Password?

or

Please Try Again {{ error }}

Send my password

SUCCESS
An email was sent with password retrieval instructions. Please go to the link in the email message to retrieve your password.

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.

Increased Cannabis Interest Paves Way for Cannabinoid Production

Omri Wallach Omri Wallach, Stockhouse
0 Comments| June 10, 2020

{{labelSign}}  Favorites
{{errorMessage}}



Click to enlargeAs the cannabis market has started to recover amidst the COVID-19 pandemic, investors are looking at where the market can grow.

One leading candidate is cannabinoid production. THC, CBD, and other specific cannabinoids can be useful for a variety of treatments, including for pain, anxiety, obesity, and other significant indications. With the health and wellness sector of cannabis slated to grow, the manufacturing of targeted, 100% pure cannabinoids can lead to profitability.

Some of the highest quality cannabinoids in the business come from Canadian-based Willow Biosciences Inc. (TSX:WLLW, OTC:CANSF, Forum). The biotechnology company has been using biosynthesis to develop pharmaceutical-grade, plant-derived cannabinoids for a variety of markets, and they've had a busy 2020 with impressive steps taken in CBD production and partnerships secured with development partners.

Now, with the CBD market continuing to open up, Willow Biosciences is on track for commercialization six months ahead of schedule. What does that road-map look like, and how does biosynthesis get the Company there? CEO Trevor Peters joined Omri Wallach of Stockhouse Media remotely to discuss the technology advantage of Willow Biosciences and the evolving CBD market.



Listen on Apple PodcastsListen on Google Podcasts


FULL DISCLOSURE: This is a paid podcast produced by Stockhouse Publishing.


{{labelSign}}  Favorites
{{errorMessage}}

Comments

No comments yet. Be first to comment!

Leave a Comment

You must be logged in to be able to post a comment.

Get the latest news and updates from Stockhouse on social media

Follow STOCKHOUSE Today